Pfizer’s Mylotarg looks set for a return to the US market after FDA advisers recommended its use in acute myeloid leukaemia. The drug comes with a fascinating history, and in many ways was a ...

Pfizer will have to cut the price of its leukaemia drug Mylotarg to get regular funding from the NHS, after England’s NICE said it could only be used in about 35% of eligible patients.

Pfizer Inc’s (NYSE:PFE) Mylotarg is indicated for newly diagnosed CD33-positive AML in adults and relapsed or refractory AML CD33-positive acute myeloid leukemia in adults and pediatric patients ...

All those efforts led to the US Food and Drug Administration approving the first ADC, Mylotarg, for the treatment of acute myeloid leukemia in 2000 and to a surge of ADCs in the pharma pipeline ...

The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit. The full text of the ...